Noxopharm (ASX: NOX) confirms the presentation of clinical data concerning NOX66 (Veyonda®) to the 46th Annual Scientific Meeting of the Clinical Oncology Society of Australia (12th-14th November 2019).
DARRT-1 involves a total of 25 treated patients. The conference data concerns the end-of-study outcome for the 14 men originally enrolled in the first arm of the study and who have completed their 6-month review. The 6-month data on the final 11 patients is due to be released late-November 2019.
For more information, download the attached PDF.
Download this document
